CN113929778A

CN113929778A - Anti-myoglobin antibody and kit

Info

Publication number: CN113929778A
Application number: CN202010672665.2A
Authority: CN
Inventors: 崔鹏; 何志强; 孟媛; 钟冬梅; 叶颖; 覃婷; 王晨
Original assignee: Dongguan Pengzhi Biotechnology Co Ltd
Current assignee: Dongguan Pengzhi Biotechnology Co Ltd
Priority date: 2020-07-14
Filing date: 2020-07-14
Publication date: 2022-01-14

Abstract

The invention discloses an anti-myoglobin antibody and a kit, and relates to the technical field of antibodies. The antibodies or functional fragments thereof disclosed herein comprise a heavy chain complementarity determining region and a light chain complementarity determining region. The antibody or the functional fragment thereof has better binding capacity and affinity to myoglobin, and the kit using the antibody or the functional fragment thereof has better specificity and sensitivity for detecting myoglobin.

Description

Anti-myoglobin antibody and kit

Technical Field

The invention relates to the technical field of antibodies, and particularly relates to an anti-myoglobin antibody and a kit.

Background

Myoglobin (Mb) is a protein that stores and distributes oxygen to mammalian cells, primarily myocytes, and its oxygen saturation curve is hyperbolic. It is composed of a polypeptide chain and a prosthetic heme, has a relative molecular mass of 16700 and contains 153 amino acid residues. Apomyoglobin from which heme is removed is called globin (globin), which has significant homology with the subunits of hemoglobin (a-globin chain and P-globin chain) in amino acid sequence, and their conformation and function are also very similar.

The hydrophobic side chains on amino acid residues in a polypeptide chain of the myoglobin are mostly positioned in the molecule, the hydrophilic side chains are mostly positioned on the surface of the molecule to form a compact spherical three-dimensional structure with good water solubility and good water solubility, polar amino acids are distributed on the surface of the molecule, a pocket-shaped cavity is formed in the cavity, and the heme is kept at a stable position in the cavity. This conformation is very favorable for oxygen transport and storage, while also stabilizing heme in the polypeptide chain. Myoglobin reversibly binds oxygen, transports oxygen from the blood of capillaries near myocytes to myocytes through the cell membrane, in MbO₂The oxygen is temporarily stored in the form of oxygen, and can carry oxygen to move in muscles, and the oxygen is released when the muscles move sharply, so that the requirement of the oxygen when the muscles are strongly metabolized is ensured. Increased myoglobin expression levels are one of the mechanisms by which animals adapt to hypoxia. Therefore, under the condition of low oxygen partial pressure, the tissue can store oxygen through the myoglobin and promote the oxygen diffusion to the cells, thereby supplying oxygen to mitochondria and being beneficial to improving the oxygen diffusion of the tissue, so the myoglobin is O₂Storage of, PO₂The buffer (2) plays an important role in promoting the diffusion of oxygen.

The acute myocardial infarction is mainly caused by the rapid increase of myocardial oxygen consumption caused by various inducers clinically, and patients with coronary heart disease have continuous ischemia and anoxia caused by the fact that coronary arteries are hardened and narrowed and cannot be fully expanded, so that the rapid diagnosis reagent of cardiac troponin I/myoglobin/creatine kinase isoenzyme (CK-MB) is adopted at present and can be used as rapid auxiliary diagnosis in sudden myocardial infarction. Wherein the myoglobin can be used as an early diagnosis marker of AMI (acute myocardial infarction): the method can be used for early diagnosis of acute myocardial infarction by dynamically detecting the level of the secondary serum myoglobin. If the second detection value is obviously higher than the first detection value, the method has extremely high positive forecast value.

Detection of myoglobin can be used for exclusion diagnosis of AMI: due to the fact that the myoglobin has a short half life (15min), the myoglobin does not rise 6-12 hours after the onset of chest pain, diagnosis of AMI is facilitated to be eliminated, and the method is a good index for screening AMI; if there is no difference between the two dynamic detection measurement values, the method has a negative prediction value of 100% and excludes the possibility of acute myocardial infarction.

The detection of myoglobin also allows estimation of the range of myocardial infarction: according to the early estimation of the dynamic change curve, the myocardial hemoglobin peak value is less than 10 times of the upper limit of the reference value, the myocardial infarction range of the patient with short peak duration is smaller, while the myocardial hemoglobin peak value is more than 10 times of the upper limit of the reference value, the peak duration is longer or the myocardial infarction range of the patient is larger.

The detection of myoglobin can also be observed for the presence or absence of reocclusion or reoxpansion: since myoglobin is rapidly cleared from the kidney after AMI, the myoglobin can be completely recovered to a normal level within l 8-30 hours of onset. The myoglobin assay thus facilitates the observation of the presence or absence of reocclusion or reoccurrence of infarctions during AMI. If the peak period lasts longer than 24 hours, the heart is recovered to be normal and slow, and more than 4 days, or the descending process rises again to form double peaks and multiple peaks, the heart peduncle extension is possible or new parts are subjected to heart peduncles.

In addition, the accuracy of the detection of myoglobin for judging the re-introduction of thrombolysis can reach more than 95 percent; has profound clinical application value for predicting the prognosis of AMH and the like.

The myoglobin determination method is established by Reynafraje et al as early as 1963, but the method has poor sensitivity and is only suitable for detecting samples with higher content, and with the continuous development of analysis technology, methods such as a High Performance Liquid Chromatography (HPLC) method, an ultrafiltration method, a spectrophotometric method, an electrophoresis method, a chromatographic method, a latex enhanced transmission turbidimetric method, an enzyme-linked immunosorbent assay (ELISA) based on an immunological principle, chemiluminescence, colloidal gold and the like are developed in sequence. Spectrophotometry, High Performance Liquid Chromatography (HPLC), ultrafiltration, spectrophotometry, electrophoresis and chromatography require special equipment, the method is interfered by more factors and the sensitivity is not enough, so the method can not be widely applied clinically, and the current mainstream is enzyme-linked immunosorbent assay (ELISA) based on immune principle, chemiluminescence, colloidal gold and the like.

These assays are based on specific monoclonal antibodies, all of which require specific monoclonal antibodies against myoglobin. The existing monoclonal antibody for detecting myoglobin has defects in sensitivity, specificity and affinity and has a larger space for improvement, and the field still has strong demand for the monoclonal antibody for detecting myoglobin.

Disclosure of Invention

The invention aims to provide an anti-myoglobin antibody and a kit. The antibody or the functional fragment thereof provided by the invention has binding capacity and better affinity to myoglobin, the specificity and sensitivity for detecting myoglobin are better, the antibody or the functional fragment thereof can be used for detecting myoglobin and diagnosing myoglobin level abnormal diseases, and the invention provides more reagent choices for detecting myoglobin and diagnosing myoglobin level abnormal diseases.

The invention is realized by the following steps:

in one aspect, the invention provides an anti-myoglobin antibody or functional fragment thereof, said antibody or functional fragment thereof comprising the complementarity determining regions:

complementarity determining region CDR1-VH (heavy chain complementarity determining region 1) having the amino acid sequence G-Y-X1-F-T-X2-Y-X3-M-H, wherein: x1 is T or S, X2 is T or S, X3 is L, V or I;

a complementarity determining region CDR2-VH having the amino acid sequence Y-X1-X2-P-Y-X3-Y-D-T-K-Y-N-X4-K-F, wherein: x1 is I, V or L, X2 is N, Y or H, X3 is Q or N, X4 is E or D;

a complementarity determining region CDR3-VH having the amino acid sequence X1-R-G-G-X2-F, wherein: x1 is T or A, X2 is N, D or E;

complementarity determining region CDR1-VL (light chain complementarity determining region 1), having the amino acid sequence X1-A-S-S-S-X2-Y-P-S-Y-X3-Y, wherein: x1 is S or T; x2 is I, V or L; x3 is I or L;

a complementarity determining region CDR2-VL having the amino acid sequence T-T-S-X1-X2-A-S, wherein: x1 is Q or H; x2 is I, V or L;

a complementarity determining region CDR3-VL having the amino acid sequence X1-Q-X2-H-R-S-R, wherein: x1 is Q, H or F; x2 is Y or W.

The antibody or the functional fragment thereof with the complementarity determining region can be specifically combined with myoglobin, has better affinity to the myoglobin, has better specificity and sensitivity when being used for detecting the myoglobin, can be used for assisting in diagnosing diseases related to the abnormal myoglobin level, and provides more reagent selections for detecting the myoglobin and diagnosing the abnormal myoglobin level diseases.

In alternative embodiments, in the complementarity determining region CDR1-VH, X1 is T;

in the complementarity determining region CDR2-VH, X3 is N;

in the complementarity determining region CDR1-VL, X1 is T;

in the complementarity determining region CDR2-VL, X1 is H;

in the complementarity determining region CDR3-VL, X2 is Y.

In alternative embodiments, the antibody or functional fragment thereof has K with myoglobin_D≤4.2×10^- ⁷Affinity of mol/L.

In an alternative embodiment, K_D≤4.0×10^-7mol/L、K_D≤3.0×10^-7mol/L、K_D≤2.0×10^- ⁷mol/L、K_D≤1.0×10^-7mol/L、K_D≤9.0×10^-8mol/L、K_D≤8.0×10^-8mol/L、K_D≤7.0×10^-8mol/L、K_D≤6.0×10^-8mol/L、K_D≤5.0×10^-8mol/L、K_D≤4.0×10^-8mol/L、K_D≤3.0×10^-8mol/L or K_D≤2.0×10^-8mol/L。

In an alternative embodiment, 2.10 × 10^-8mol/L≤K_D≤4.86×10^-8mol/L。

K_DThe detection of (2) is carried out with reference to the method of the present embodiment.

In an alternative embodiment, in the complementarity determining region CDR1-VH, X2 is T.

In an alternative embodiment, in the complementarity determining region CDR1-VH, X2 is S.

In an alternative embodiment, in the complementarity determining region CDR1-VH, X3 is L.

In an alternative embodiment, in the complementarity determining region CDR1-VH, X3 is V.

In an alternative embodiment, in the complementarity determining region CDR1-VH, X3 is I.

In an alternative embodiment, in the complementarity determining region CDR2-VH, X1 is L.

In an alternative embodiment, in the complementarity determining region CDR2-VH, X1 is V.

In an alternative embodiment, in the complementarity determining region CDR2-VH, X1 is I.

In an alternative embodiment, in the complementarity determining region CDR2-VH, X2 is N.

In an alternative embodiment, in the complementarity determining region CDR2-VH, X2 is Y.

In an alternative embodiment, in the complementarity determining region CDR2-VH, X2 is H.

In an alternative embodiment, in the complementarity determining region CDR2-VH, X4 is E.

In an alternative embodiment, in the complementarity determining region CDR2-VH, X4 is D.

In an alternative embodiment, in the complementarity determining region CDR3-VH, X1 is T.

In an alternative embodiment, in the complementarity determining region CDR3-VH, X1 is a.

In an alternative embodiment, in the complementarity determining region CDR3-VH, X2 is N.

In an alternative embodiment, in the complementarity determining region CDR3-VH, X2 is D.

In an alternative embodiment, in the complementarity determining region CDR3-VH, X2 is E.

In an alternative embodiment, in the complementarity determining region CDR1-VL, X2 is I.

In an alternative embodiment, in the complementarity determining region CDR1-VL, X2 is V.

In an alternative embodiment, in the complementarity determining region CDR1-VL, X2 is L.

In an alternative embodiment, in the complementarity determining region CDR1-VL, X3 is I.

In an alternative embodiment, in the complementarity determining region CDR1-VL, X3 is L.

In an alternative embodiment, in the complementarity determining region CDR2-VL, X2 is I.

In an alternative embodiment, in the complementarity determining region CDR2-VL, X2 is V.

In an alternative embodiment, in the complementarity determining region CDR2-VL, X2 is L.

In an alternative embodiment, in the complementarity determining region CDR3-VL, X1 is Q.

In an alternative embodiment, in the complementarity determining region CDR3-VL, X1 is H.

In an alternative embodiment, in the complementarity determining region CDR3-VL, X1 is F.

In alternative embodiments, the mutation site of each complementarity determining region of the antibody or functional fragment thereof is selected from any one of the following combinations of mutations 1-54:

in alternative embodiments, in the complementarity determining region CDR1-VH, X1 is S;

in the complementarity determining region CDR2-VH, X3 is Q;

in the complementarity determining region CDR1-VL, X1 is S;

in the complementarity determining region CDR2-VL, X1 is Q;

in the complementarity determining region CDR3-VL, X2 is W.

In alternative embodiments, the mutation site of each complementarity determining region of the antibody or functional fragment thereof is selected from any one of the following combinations of mutations 54-61:

in alternative embodiments, the antibody comprises the light chain framework regions FR1-L, FR2-L, FR3-L and FR4-L in sequence as set forth in SEQ ID NOS: 1-4, and/or the heavy chain framework regions FR1-H, FR2-H, FR3-H and FR4-H in sequence as set forth in SEQ ID NOS: 5-8.

In general, the variable regions of the heavy chain (VH) and light chain (VL) can be obtained by linking the CDRs and FRs numbered below in a combined arrangement as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR 4.

It is noted that in other embodiments, each framework region amino acid sequence of an antibody or functional fragment thereof provided herein can have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology to the corresponding framework region described above (SEQ ID NO:1, 2, 3, 4, 5, 6, 7, or 8).

In alternative embodiments, the antibody further comprises a constant region.

In alternative embodiments, the constant region is selected from the constant regions of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD.

In alternative embodiments, the species of the constant region is derived from a cow, horse, dairy cow, pig, sheep, goat, rat, mouse, dog, cat, rabbit, camel, donkey, deer, mink, chicken, duck, goose, turkey, chicken fountains, or human.

In alternative embodiments, the constant region is derived from a mouse.

In alternative embodiments, the light chain constant region sequence of the constant region is set forth in SEQ ID NO. 9 and the heavy chain constant region sequence of the constant region is set forth in SEQ ID NO. 10.

In alternative embodiments, the functional fragment is selected from any one of VHH, F (ab ') 2, Fab', Fab, Fv and scFv of the antibody.

In another aspect, the present invention provides a reagent or a kit for detecting myoglobin, which comprises the antibody or the functional fragment thereof as described in any one of the above.

Functional fragments of the above antibodies typically have the same binding specificity as the antibody from which they are derived. As will be readily understood by those skilled in the art based on the teachings of the present invention, functional fragments of the above antibodies can be obtained by methods such as enzymatic digestion (including pepsin or papain) and/or by chemical reduction to cleave disulfide bonds.

Functional fragments of the above antibodies can also be obtained by recombinant genetic techniques also known to those skilled in the art or synthesized by, for example, automated peptide synthesizers, such as those sold by Applied BioSystems and the like.

In another aspect, the present invention provides the use of the antibody or functional fragment thereof according to any one of the above in the preparation of a reagent or kit for diagnosing a disease with abnormal myoglobin levels.

In an alternative embodiment, the disorder of abnormal myoglobin levels is selected from one of acute myocardial infarction and acute coronary syndrome.

In another aspect, the present invention provides a method for detecting myoglobin, comprising: mixing the antibody or functional fragment thereof according to any one of the above with a sample to be tested.

It should be noted that those skilled in the art can perform qualitative or quantitative detection of myoglobin in the sample to be tested based on the characteristics of immune complex formed by antibody/antigen combination. The method for detecting an antigen or an antibody based on the formation of an immune complex upon binding of the antibody to the antigen comprises:

(1) the detection purpose is realized by a precipitation reaction, which comprises the following steps: a one-way immunodiffusion test, a two-way immunodiffusion test, an immunoturbidimetry, a countercurrent immunoelectrophoresis, an immunoblotting, and the like;

(2) the detection purpose is realized by marking an indicator for displaying the signal intensity, and the method comprises the following steps: immunofluorescence, radioimmunoassay, enzyme-linked immunoassay (e.g., double antibody sandwich, indirect or competitive assay), and chemiluminescence immunoassay.

The indicator may be selected appropriately according to different detection methods, including but not limited to the indicators described below:

(a) in the immunofluorescence method, the indicator may be a fluorescent dye, for example, a fluorescein-based dye (including Fluorescein Isothiocyanate (FITC) hydroxyphoton (FAM), tetrachlorofluorescein (TET), etc. or an analog thereof), a rhodamine-based dye (including red Rhodamine (RBITC), Tetramethylrhodamine (TAMRA), rhodamine b (tritc), etc. or an analog thereof), a Cy-series dye (including Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy3, etc. or an analog thereof), an Alexa-series dye (including Alexa fluor350, 405, 430, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750, etc. or an analog thereof), a protein-based dye (including Phycoerythrin (PE), Phycocyanin (PC), allophycocyanin (allophycocyanin), polymetaxanthin-chlorophyll protein (preCP), etc.);

(b) in radioimmunoassays, the indicator may be a radioisotope, including but not limited to²¹²Bi、¹³¹I、¹¹¹In、⁹⁰Y、¹⁸⁶Re、²¹¹At、¹²⁵I、¹⁸⁸Re、¹⁵³Sm、²¹³Bi、³²P、⁹⁴mTc、⁹⁹mTc、²⁰³Pb、⁶⁷Ga、⁶⁸Ga、⁴³Sc、⁴⁷Sc、¹¹⁰mIn、⁹⁷Ru、⁶²Cu、⁶⁴Cu、⁶⁷Cu、⁶⁸Cu、⁸⁶Y、⁸⁸Y、¹²¹Sn、¹⁶¹Tb、¹⁶⁶Ho、¹⁰⁵Rh、¹⁷⁷Lu、¹⁷²Lu and¹⁸F。

(c) in enzyme-linked immunoassays, the indicator may be an enzyme that catalyzes the development of a substrate (e.g., horseradish peroxidase, alkaline phosphatase, or glucose oxidase, etc.).

(d) In chemiluminescent immunoassays, the indicator may be a chemiluminescent reagent such as acridinium ester, horseradish peroxidase and luminol, alkaline phosphatase and AMPPD, electrochemiluminescent agents ruthenium and tripropylamine, and the like.

Based on the above, on the basis of the disclosure of the antibody or the functional fragment thereof, those skilled in the art can easily think of using any one of the above methods or a combination of several methods or other methods to achieve quantitative or qualitative detection of myoglobin in the sample to be detected, and it is within the scope of the present invention to use the antibody or the functional fragment thereof disclosed in the present invention to detect myoglobin regardless of the method selected.

In alternative embodiments, the indicator is selected from any one of a fluorescent dye, a radioisotope, an enzyme that catalyzes the color development of a substrate, and a chemiluminescent reagent.

In another aspect, the present invention provides a vector comprising a nucleic acid encoding the antibody or functional fragment thereof according to any one of the above.

In alternative embodiments, the nucleic acid is DNA or RNA.

Based on the disclosure of the amino acid sequence of the above antibody or functional fragment thereof, one skilled in the art can easily obtain the nucleic acid sequence encoding the above antibody or functional fragment thereof according to the codon corresponding to the amino acid, and obtain various nucleic acid sequences encoding the above antibody or functional fragment thereof according to the degeneracy of the codon, which is within the protection scope of the present invention as long as it encodes the above antibody or functional fragment thereof.

In another aspect, the present invention provides a host cell comprising a vector as described above.

The above-described nucleic acid sequences in the vector are operably linked to at least one regulatory sequence. "operably linked" means that the nucleic acid sequence is linked to the regulatory sequence in a manner that allows expression. Regulatory sequences, including promoters, enhancers and other expression control elements, are selected to direct the expression of the protein of interest in a suitable host cell.

Herein, a vector may refer to a molecule or agent comprising a nucleic acid of the invention or a fragment thereof, capable of carrying genetic information and capable of delivering the genetic information into a cell. Typical vectors include plasmids, viruses, bacteriophages, cosmids and minichromosomes. The vector may be a cloning vector (i.e., a vector for transferring genetic information into a cell, which may be propagated and in which the genetic information may be present or absent) or an expression vector (i.e., a vector which comprises the necessary genetic elements to permit expression of the genetic information of the vector in a cell). Thus, a cloning vector may contain a selectable marker, as well as an origin of replication compatible with the cell type specified by the cloning vector, while an expression vector contains the regulatory elements necessary to effect expression in a specified target cell.

The nucleic acid of the invention or fragments thereof may be inserted into a suitable vector to form a cloning or expression vector carrying the nucleic acid fragment of the invention. Such novel vectors are also part of the present invention. The vector may comprise a plasmid, phage, cosmid, minichromosome, or virus, as well as naked DNA that is transiently expressed only in a particular cell. The cloning and expression vectors of the invention are capable of autonomous replication and thus provide high copy numbers for high level expression or high level replication purposes for subsequent cloning. The expression vector may comprise a promoter for driving expression of the nucleic acid fragment of the invention, optionally a signal peptide sequence encoding for secretion or integration of the protein expression product into a membrane, and optionally a nucleic acid sequence encoding for a terminator. When the expression vector is manipulated in a production strain or cell line, the vector, when introduced into a host cell, may or may not be integrated into the genome of the host cell. Vectors typically carry a replication site, as well as a marker sequence capable of providing phenotypic selection in transformed cells.

In another aspect, the present invention provides a method of producing an antibody or functional fragment thereof as described above, comprising:

culturing the host cell as described above, and isolating and purifying the antibody or functional fragment thereof from the culture medium or from the cultured host cell.

The production method may be, for example, transfecting a host cell with a nucleic acid vector encoding at least a portion of the antibody or functional fragment thereof, and culturing the host cell under suitable conditions to express the antibody or functional fragment thereof. The host cell may also be transfected with one or more expression vectors, which may comprise, alone or in combination, DNA encoding at least a portion of the antibody or functional fragment thereof. Antibodies or functional fragments thereof can be isolated from culture media or cell lysates using conventional techniques for purifying proteins and peptides, including ammonium sulfate precipitation, chromatography (e.g., ion exchange, gel filtration, affinity chromatography, etc.), and/or electrophoresis.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.

FIG. 1 is a reduced SDS-PAGE of the myoglobin monoclonal antibody of example 1.

Detailed Description

In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the formulations or unit dosages herein, some are now described. Unless otherwise indicated, the techniques employed or contemplated herein are standard methods. The materials, methods, and examples are illustrative only and not intended to be limiting.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry and immunology, which are within the skill of the art. Such techniques are well explained in the literature, e.g. "molecular cloning: a Laboratory Manual, second edition (Sambrook et al, 1989); oligonucleotide Synthesis (oligo Synthesis) (eds. m.j. goal, 1984); animal Cell Culture (Animal Cell Culture), ed.r.i. freshney, 1987; methods in Enzymology (Methods in Enzymology), Handbook of Experimental Immunology (Handbook of Experimental Immunology) (ed. D.M.Weir and C.C.Black well), Gene Transfer Vectors for Mammalian Cells (ed. J.M.Miller and M.P.Calos) (ed. J.M.and M.P.Calos) (ed. 1987), Methods in Current Generation (Current Protocols in Molecular Biology) (ed. F.M.Ausubel.et al, 1987), PCR, Polymerase Chain Reaction (ed. PCR: The Polymerase Chain Reaction) (ed. Mullis et al, 1994), and Methods in Current Immunology (ed. J.1991).

Several aspects of the invention are described below with reference to example applications for illustration. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the invention. One of ordinary skill in the relevant art will readily recognize, however, that the invention can be practiced without one or more of the specific details or with other methods. The present invention is not limited by the illustrated ordering of activities or events, as some activities may occur in different orders and/or concurrently with other activities or events. Moreover, not all illustrated acts or events are required to implement a methodology in accordance with the present invention.

The features and properties of the present invention are described in further detail below with reference to examples.

Example 1

Restriction enzyme, Prime Star DNA polymerase, was purchased from Takara in this example. MagExtractor-RNA extraction kit was purchased from TOYOBO. BD SMART^TMRACE cDNA Amplification Kit was purchased from Takara. pMD-18T vector was purchased from Takara. Plasmid extraction kits were purchased from Tiangen corporation. Primer synthesis and gene sequencing were performed by Invitrogen corporation.

1 construction of recombinant plasmid

(1) Antibody Gene preparation

mRNA is extracted from a hybridoma cell strain (11D2) secreting an anti-myoglobin monoclonal antibody, a DNA product is obtained by an RT-PCR method, the product is added with A by rTaq DNA polymerase for reaction and then inserted into a pMD-18T vector, the product is transformed into DH5 alpha competent cells, and after colonies are grown, 4 clones of the Heavy Chain and Light Chain gene clones are respectively taken and sent to a gene sequencing company for sequencing.

(2) Sequence analysis of antibody variable region genes

Putting the gene sequence obtained by sequencing in an IMGT antibody database for analysis, and analyzing by using VNTI11.5 software to determine that the genes amplified by the heavy Chain primer pair and the Light Chain primer pair are correct, wherein in the gene fragment amplified by the Light Chain, the VL gene sequence is 324bp, belongs to VkII gene family, and a leader peptide sequence of 57bp is arranged in front of the VL gene sequence; in the gene fragment amplified by the Heavy Chain primer pair, the VH gene sequence is 345bp, belongs to a VH1 gene family, and has a leader peptide sequence of 57bp in front.

(3) Construction of recombinant antibody expression plasmid

pcDNA^TM3.4

vector is a constructed recombinant antibody eukaryotic expression vector, and multiple cloning enzyme cutting sites such as HindIII, BamHI, EcoRI and the like are introduced into the expression vector and named as pcDNA3.4A expression vector, and the vector is called as 3.4A expression vector for short in the following; according to the sequencing result of the antibody variable region gene in the pMD-18T, VL and VH gene specific primers of the antibody are designed, two ends of the primers are respectively provided with HindIII and EcoRI restriction sites and protective bases, and a Light Chain gene fragment of 0.73KB and a Heavy Chain gene fragment of 1.42KB are amplified by a PCR amplification method.

The gene fragments of the Heavy Chain and the Light Chain are subjected to double enzyme digestion by HindIII/EcoRI respectively, the 3.4A vector is subjected to double enzyme digestion by HindIII/EcoRI, the Heavy Chain gene and the Light Chain gene are respectively connected into the 3.4A expression vector after the fragments and the vector are purified and recovered, and recombinant expression plasmids of the Heavy Chain and the Light Chain are respectively obtained.

2 Stable cell line selection

(1) Transient transfection of recombinant antibody expression plasmid into CHO cells and determination of expression plasmid activity

Plasmid was diluted to 400ng/ml with ultrapure water and CHO cells were conditioned at 1.43X 10⁷cells/ml are put into a centrifuge tube, 100ul of plasmid is mixed with 700ul of cells, the mixture is transferred into an electric rotating cup and is electrically rotated, sampling and counting are carried out on days 3, 5 and 7, and sampling and detecting are carried out on day 7.

The coating solution dilutes the recombinant myoglobin (produced by oneself) to 1ug/ml, 100uL per well, and stays overnight at 4 ℃; the next day, washing with the washing solution for 2 times, and patting dry; adding blocking solution (20% BSA + 80% PBS), beating to dry at 37 deg.C for 1h and 120uL per well; adding diluted cell supernatant at 100 uL/well at 37 deg.C for 30min (partial supernatant for 1 h); washing with washing solution for 5 times, and drying; adding goat anti-mouse IgG-HRP (goat anti-mouse IgG-HRP) with the concentration of 100uL per well at 37 ℃ for 30 min; washing with washing solution for 5 times, and drying; adding a developing solution A (50 uL/hole, containing citric acid, sodium acetate, acetanilide and carbamide peroxide), and adding a developing solution B (50 uL/hole, containing citric acid, EDTA-2 Na, TMB and concentrated HCL) for 10 min; adding stop solution (50 uL/hole, EDTA & 2Na + concentrated H2SO 4); OD readings were taken at 450nm (reference 630nm) on the microplate reader. The results show that the OD of the reaction after the cell supernatant is diluted 1000 times is still larger than 1.0, and the OD of the reaction without the cell supernatant is smaller than 0.1, which indicates that the antibody generated after the plasmid is transiently transformed has activity on the myoglobin.

(2) Linearization of recombinant antibody expression plasmids

The following reagents were prepared: 50ul Buffer, 100 ug/tube DNA, 10ul Puv I enzyme and sterile water to 500ul, and performing enzyme digestion in water bath at 37 ℃ overnight; sequentially extracting with equal volume of phenol/chloroform/isoamyl alcohol (lower layer) 25:24:1 and then chloroform (water phase); precipitating with 0.1 volume (water phase) of 3M sodium acetate and 2 volumes of ethanol on ice, rinsing with 70% ethanol, removing organic solvent, re-melting with appropriate amount of sterilized water after ethanol is completely volatilized, and finally measuring concentration.

(3) Stable transfection of recombinant antibody expression plasmid, pressurized screening of stable cell lines

Plasmid was diluted to 400ng/ml with ultrapure water and CHO cells were conditioned at 1.43X 10⁷Putting cells/ml in a centrifuge tube, mixing 100ul plasmid and 700ul cells, transferring into an electric rotating cup, electrically rotating, and counting the next day; 25umol/L MSX 96-well pressure culture for about 25 days.

Observing the marked clone holes with cells under a microscope, and recording the confluence degree; taking culture supernatant, and sending the culture supernatant to a sample for detection; selecting cell strains with high antibody concentration and relative concentration, transferring the cell strains into 24 holes, and transferring the cell strains into 6 holes after 3 days; after 3 days, the seeds were kept and cultured in batches, and the cell density was adjusted to 0.5X 10⁶cells/ml, 2.2ml, cell density 0.3X 10⁶cell/ml, 2ml for seed preservation; and (4) 7 days, carrying out batch culture supernatant sample sending detection in 6 holes, and selecting cell strains with small antibody concentration and cell diameter to transfer TPP for seed preservation and passage.

3 recombinant antibody production

(1) Cell expanding culture

After the cells are recovered, the cells are cultured in a shaking flask with the specification of 125ml, the inoculation volume is 30ml, the culture medium is 100% Dynamis culture medium, and the cells are placed in a shaking table with the rotation speed of 120r/min, the temperature of 37 ℃ and the carbon dioxide of 8%. Culturing for 72h, inoculating and expanding culture at an inoculation density of 50 ten thousand cells/ml, wherein the expanding culture volume is calculated according to production requirements, and the culture medium is 100% Dynamis culture medium. Then the culture is expanded every 72 h. When the cell amount meets the production requirement, the production is carried out by strictly controlling the inoculation density to be about 50 ten thousand cells/ml.

(2) Shake flask production and purification

Shake flask parameters: the rotating speed is 120r/min, the temperature is 37 ℃, and the carbon dioxide is 8 percent. Feeding in a flowing mode: daily feeding was started when the culture was carried out for 72h in a shake flask, 3% of the initial culture volume was fed daily to HyCloneTM Cell BoostTM Feed 7a, and one thousandth of the initial culture volume was fed daily to Feed 7b, up to day 12 (day 12 feeding). Glucose was supplemented with 3g/L on the sixth day. Samples were collected on day 13. Affinity purification was performed using a proteinA affinity column. Mu.g of the purified antibody was subjected to reducing SDS-PAGE, and 4. mu.g of an external control antibody was used as a control, and the electrophorogram shown in FIG. 1 showed two bands, one of which showed 50KD (heavy chain, SEQ ID NO.14) and the other of which showed 28KD (light chain, SEQ ID NO.13) after reducing SDS-PAGE.

Example 2

Detection of antibody Performance

(1) Example 1 Activity assay of antibodies and mutants thereof

Further analysis revealed that the variable region of the heavy chain of myoglobin monoclonal antibody (WT) of example 1 is shown in SEQ ID NO:12, wherein the amino acid sequences of the complementarity determining regions are as follows:

CDR1-VH：G-Y-S(X1)-F-T-S(X2)-Y-I(X3)-M-H；

CDR2-VH：Y-I(X1)-H(X2)-P-Y-Q(X3)-Y-D-T-K-Y-N-D(X4)-K-F；

CDR3-VH：A(X1)-R-G-G-N(X2)-F；

the light chain variable region is shown as SEQ ID NO. 11, wherein the amino acid sequences of the complementarity determining regions of the light chain are as follows:

CDR1-VL：S(X1)-A-S-S-S-V(X2)-Y-P-S-Y-I(X3)-Y；

CDR2-VL：T-T-S-Q(X1)-I(X2)-A-S；

CDR3-VL：H(X1)-Q-W(X2)-H-R-S-R。

on the basis of the myoglobin monoclonal antibody of example 1, mutations were made in the complementarity determining regions at sites relevant to the activity of the antibody, wherein X1, X2, X3 and X4 were all mutated sites. See table 1 below.

TABLE 1 mutant sites associated with antibody Activity

And (3) detecting the binding activity:

diluting the recombinant myoglobin to 1 mu g/ml by coating solution (PBS) to carry out microplate coating, wherein each well is 100 mu l, and the temperature is kept overnight at 4 ℃; the next day, washing with the washing solution for 2 times, and patting dry; adding blocking solution (20% BSA + 80% PBS), beating to dry at 37 deg.C for 1 hr, and adding blocking solution (120 μ l per well); adding diluted myoglobin monoclonal antibody at a concentration of 100 μ l/well at 37 deg.C for 30-60 min; washing with washing solution for 5 times, and drying; adding goat anti-mouse IgG-HRP (goat anti-mouse IgG-HRP) with the concentration of 100 mu l per well at 37 ℃ for 30 min; washing with washing solution (PBS) for 5 times, and drying; adding color development liquid A (50 μ L/well containing 2.1g/L citric acid, 12.25g/L citric acid, 0.07g/L acetanilide and 0.5g/L carbamide peroxide) and adding color development liquid B (50 μ L/well containing 1.05g/L citric acid, 0.186g/L LEDTA.2Na, 0.45g/L TMB and 0.2ml/L concentrated HCl) for 10 min; stop solution (50. mu.l/well, containing 0.75 g/EDTA-2 Na and 10.2ml/L concentrated H) was added₂SO₄) (ii) a OD readings were taken at 450nm (reference 630nm) on the microplate reader. The results are shown in Table 2.

TABLE 2 Activity data of antibodies and mutants thereof

Antibody concentration (ng/ml)	500	250	125	62.5	31.25	0
							WT	1.264	1.119	0.829	0.685	0.378	0.065
Mutation 1	1.312	1.224	1.118	0.817	0.495	0.058
							Mutation 2	1.205	1.156	1.003	0.789	0.511	0.049
Mutation 3	1.297	1.138	1.104	0.798	0.522	0.052
							Mutation 4	1.208	1.107	1.067	0.704	0.517	0.058
Mutation 5	0.825	0.621	0.378	-	-	-
							Mutation 6	0.736	0.533	0.324	-	-	-
Mutation 7	0.784	0.422	0.451	-	-	-

As can be seen from the activity data in table 2, the binding activity of WT as well as mutant 1-4 antibodies was superior to that of mutations 5-7, indicating the mutation sites in table 1: the types of amino acid residue mutations of CDR1-VH X1, CDR2-VH X3, and CDR1-VL X1 have an effect on antibody binding activity and are unpredictable.

(2) Example 1 affinity assays for antibodies and mutants thereof

(a) Based on mutation 1, other sites were mutated, and the sequence of each mutation is shown in table 3 below.

TABLE 3 mutation sites related to antibody affinity

And (3) affinity detection:

using AMC sensors, purified antibodies (Table 3 mutation antibody) with PBST diluted to 1mg/ml, MYO protein PBST gradient dilution;

the operation flow is as follows: equilibrating in buffer 1(PBST) for 60s, immobilizing antibody in antibody solution for 300s, incubating in buffer 2(PBST) for 180s, binding in antigen solution for 420s, dissociating in buffer 2 for 1200s, regenerating the sensor with 10mM GLY solution pH 1.69 and buffer 3, and outputting the data. K_DRepresents the equilibrium dissociation constant, i.e., affinity; kon denotes the binding rate; kdis denotes the off-rate.

Table 4 affinity assay data

The data in table 4 show that the antibodies after mutation 1 and mutation based on the above have better affinity with less difference in affinity change, which indicates that the antibodies obtained by mutation in the manner shown in table 3 have better affinity for myoglobin.

(b) Based on WT, mutation is carried out on other sites, and the affinity of each mutant is detected, the sequence of each mutation is shown in Table 5, and the corresponding affinity data is shown in Table 6.

TABLE 5 mutations with WT as backbone

TABLE 6 results of affinity assay of mutations with WT as backbone

	K_D(M)	kon(1/Ms)	kdis(1/s)
				WT	3.56E-07	3.76E+04	1.34E-02
WT-1	3.28E-07	3.96E+04	1.30E-02
				WT-2	4.20E-07	3.81E+04	1.60E-02
WT-3	4.04E-07	4.85E+04	1.96E-02
				WT-4	3.25E-07	3.20E+04	1.04E-02
WT-5	3.99E-07	3.23E+04	1.29E-02
				WT-6	3.82E-07	3.58E+04	1.37E-02
WT-7	3.92E-07	3.31E+04	1.30E-02

As can be seen from the data in Table 6, WT and its mutant antibody have good affinity for myoglobin, indicating that the resulting antibody, mutated as in Table 5, is also capable of binding myoglobin.

(3) Evaluation of stability against naked antibody

The antibody of the above example is placed in 4 ℃ (refrigerator), -80 ℃ (refrigerator), 37 ℃ (incubator) for 21 days, samples for 7 days, 14 days, 21 days are taken for state observation, and activity detection is carried out on the samples for 21 days, the result shows that under three examination conditions, no obvious protein state change is seen in 21 days of antibody placement, and the activity is not more prone to decrease with the increase of examination temperature, which indicates that the self-produced antibody is stable. The following table shows the results of the 21-day evaluation of the OD enzyme immunity assay with mutation 1.

TABLE 7

Antibody concentration (ng/ml)	250	62.5	0
				Samples at 4 ℃ for 21 days	1.208	0.799	0.052
21 days samples at-80 deg.C	1.216	0.814	0.037
				21 day samples at 37 deg.C	1.211	0.801	0.049

As can be seen from Table 7, the antibodies of the examples of the present invention can still detect antigens after being stored for 21 days at different temperatures, which indicates that the antibodies provided by the examples of the present invention have better stability.

(4) Evaluation of Performance

And (3) taking the self-produced mutation 1 antibody and the WT antibody as marker antibodies, respectively matching with other MYO coated antibodies for use, comparing the performance evaluation of the self-produced mutation 1 antibody and the WT antibody on a fluorescent rapid diagnosis and evaluation platform, and verifying the performance levels of the self-produced mutation 1 antibody and the WT antibody. The specificity, sensitivity, clinical consistency and relevance of 500 specimens tested were as follows, with specific data as shown in table 8 below:

TABLE 8

	Specificity of	Sensitivity of the probe	Consistency	Correlation
					WT antibody	100％	91.7％	95.2％	0.9192
Mutant 1 antibodies	100％	98.6％	97.0％	0.9347

The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Sequence listing

<110> Dongguan City of Pengzhi Biotech Co., Ltd

<120> myoglobin-resistant antibody and kit

<160> 14

<170> SIPOSequenceListing 1.0

<210> 1

<211> 23

<212> PRT

<213> Artificial sequence

<400> 1

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Leu Gly

1 5 10 15

Glu Arg Val Thr Met Thr Cys

20

<210> 2

<211> 15

<212> PRT

<213> Artificial sequence

<400> 2

Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr

1 5 10 15

<210> 3

<211> 32

<212> PRT

<213> Artificial sequence

<400> 3

Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser

1 5 10 15

Leu Thr Leu Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys

20 25 30

<210> 4

<211> 12

<212> PRT

<213> Artificial sequence

<400> 4

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg

1 5 10

<210> 5

<211> 25

<212> PRT

<213> Artificial sequence

<400> 5

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser

20 25

<210> 6

<211> 14

<212> PRT

<213> Artificial sequence

<400> 6

Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly

1 5 10

<210> 7

<211> 32

<212> PRT

<213> Artificial sequence

<400> 7

Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr

1 5 10 15

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys

20 25 30

<210> 8

<211> 13

<212> PRT

<213> Artificial sequence

<400> 8

Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser

1 5 10

<210> 9

<211> 106

<212> PRT

<213> Artificial sequence

<400> 9

Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln

1 5 10 15

Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr

20 25 30

Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln

35 40 45

Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr

50 55 60

Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg

65 70 75 80

His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro

85 90 95

Ile Val Lys Ser Phe Asn Arg Asn Glu Cys

100 105

<210> 10

<211> 336

<212> PRT

<213> Artificial sequence

<400> 10

Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly

1 5 10 15

Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr

20 25 30

Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser

35 40 45

Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr Met

50 55 60

Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val

65 70 75 80

Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys Lys

85 90 95

Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys

100 105 110

Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser

115 120 125

Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu

130 135 140

Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro

145 150 155 160

Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala

165 170 175

Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val

180 185 190

Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe

195 200 205

Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr

210 215 220

Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val Tyr Ile Leu

225 230 235 240

Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser Leu Thr Cys

245 250 255

Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp Thr Ser

260 265 270

Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro Val Leu Asp

275 280 285

Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys Thr Ser

290 295 300

Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His Glu Gly

305 310 315 320

Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro Gly Lys

325 330 335

<210> 11

<211> 108

<212> PRT

<213> Artificial sequence

<400> 11

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Leu Gly

1 5 10 15

Glu Arg Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Tyr Pro Ser

20 25 30

Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp

35 40 45

Ile Tyr Thr Thr Ser Gln Ile Ala Ser Gly Val Pro Ala Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Leu Ser Ser Met Glu

65 70 75 80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Trp His Arg Ser Arg

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg

100 105

<210> 12

<211> 115

<212> PRT

<213> Artificial sequence

<400> 12

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr

20 25 30

Ile Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile

35 40 45

Gly Tyr Ile His Pro Tyr Gln Tyr Asp Thr Lys Tyr Asn Asp Lys Phe

50 55 60

Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr

100 105 110

Val Ser Ser

115

<210> 13

<211> 214

<212> PRT

<213> Artificial sequence

<400> 13

Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Leu Gly

1 5 10 15

Glu Arg Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Tyr Pro Ser

20 25 30

Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp

35 40 45

Ile Tyr Thr Thr Ser Gln Ile Ala Ser Gly Val Pro Ala Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Leu Ser Ser Met Glu

65 70 75 80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Trp His Arg Ser Arg

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala

100 105 110

Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly

115 120 125

Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile

130 135 140

Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu

145 150 155 160

Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser

165 170 175

Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr

180 185 190

Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser

195 200 205

Phe Asn Arg Asn Glu Cys

210

<210> 14

<211> 451

<212> PRT

<213> Artificial sequence

<400> 14

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr

20 25 30

Ile Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile

35 40 45

Gly Tyr Ile His Pro Tyr Gln Tyr Asp Thr Lys Tyr Asn Asp Lys Phe

50 55 60

Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr

100 105 110

Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro

115 120 125

Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val

130 135 140

Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser

145 150 155 160

Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu

165 170 175

Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser

180 185 190

Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val

195 200 205

Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys

210 215 220

Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly

225 230 235 240

Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met

245 250 255

Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser Glu

260 265 270

Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val

275 280 285

His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile

290 295 300

Arg Val Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly

305 310 315 320

Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile

325 330 335

Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val

340 345 350

Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser

355 360 365

Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu

370 375 380

Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro

385 390 395 400

Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met

405 410 415

Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg

420 425 430

His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser

435 440 445

Pro Gly Lys

450

Claims

1. An anti-myoglobin antibody or functional fragment thereof, wherein said antibody or functional fragment thereof comprises the following complementarity determining regions:

a complementarity determining region CDR1-VH having the amino acid sequence G-Y-X1-F-T-X2-Y-X3-M-H, wherein: x1 is T or S, X2 is T or S, X3 is L, V or I;

a complementarity determining region CDR1-VL having the amino acid sequence X1-A-S-S-S-X2-Y-P-S-Y-X3-Y, wherein: x1 is S or T; x2 is I, V or L; x3 is I or L;

2. The antibody or functional fragment thereof according to claim 1,

in the complementarity determining region CDR1-VH, X1 is T;

in the complementarity determining region CDR2-VH, X3 is N;

in the complementarity determining region CDR1-VL, X1 is T;

in the complementarity determining region CDR2-VL, X1 is H;

in the complementarity determining region CDR3-VL, X2 is Y;

preferably, the antibody or functional fragment thereof has a K with myoglobin_D≤4.2×10^-7Affinity of mol/L, preferably, K_D≤4.86×10^-8mol/L；

Preferably, in the complementarity determining region CDR1-VH, X2 is T;

preferably, in the complementarity determining region CDR1-VH, X2 is S;

preferably, in the complementarity determining region CDR1-VH, X3 is L;

preferably, in the complementarity determining region CDR1-VH, X3 is V;

preferably, in the complementarity determining region CDR1-VH, X3 is I;

preferably, in the complementarity determining region CDR2-VH, X1 is L;

preferably, in the complementarity determining region CDR2-VH, X1 is V;

preferably, in the complementarity determining region CDR2-VH, X1 is I;

preferably, in the complementarity determining region CDR2-VH, X2 is N;

preferably, in the complementarity determining region CDR2-VH, X2 is Y;

preferably, in the complementarity determining region CDR2-VH, X2 is H;

preferably, in the complementarity determining region CDR2-VH, X4 is E;

preferably, in the complementarity determining region CDR2-VH, X4 is D;

preferably, in the complementarity determining region CDR3-VH, X1 is T;

preferably, in the complementarity determining region CDR3-VH, X1 is A;

preferably, in the complementarity determining region CDR3-VH, X2 is N;

preferably, in the complementarity determining region CDR3-VH, X2 is D;

preferably, in the complementarity determining region CDR3-VH, X2 is E;

preferably, in the complementarity determining region CDR1-VL, X2 is I;

preferably, in the complementarity determining region CDR1-VL, X2 is V;

preferably, in the complementarity determining region CDR1-VL, X2 is L;

preferably, in the complementarity determining region CDR1-VL, X3 is I;

preferably, in the complementarity determining region CDR1-VL, X3 is L;

preferably, in the complementarity determining region CDR2-VL, X2 is I;

preferably, in the complementarity determining region CDR2-VL, X2 is V;

preferably, in the complementarity determining region CDR2-VL, X2 is L;

preferably, in the complementarity determining region CDR3-VL, X1 is Q;

preferably, in the complementarity determining region CDR3-VL, X1 is H;

preferably, in the complementarity determining region CDR3-VL, X1 is F;

preferably, the mutation site of each complementarity determining region of the antibody or functional fragment thereof is selected from any one of the following mutation combinations 1 to 53:

3. the antibody or functional fragment thereof according to claim 1,

in the complementarity determining region CDR1-VH, X1 is S;

in the complementarity determining region CDR2-VH, X3 is Q;

in the complementarity determining region CDR1-VL, X1 is S;

in the complementarity determining region CDR2-VL, X1 is Q;

in the complementarity determining region CDR3-VL, X2 is W;

preferably, the mutation site of each complementarity determining region of the antibody or functional fragment thereof is selected from any one of the following combinations of mutations 54-61:

4. the antibody or functional fragment thereof according to any one of claims 1 to 3, wherein said antibody comprises the light chain framework regions FR1-L, FR2-L, FR3-L and FR4-L in sequence as set forth in SEQ ID Nos. 1-4, and/or the heavy chain framework regions FR1-H, FR2-H, FR3-H and FR4-H in sequence as set forth in SEQ ID Nos. 5-8;

preferably, the antibody further comprises a constant region;

preferably, the constant region is selected from the constant regions of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD;

preferably, the species of the constant region is from a cow, horse, cow, pig, sheep, goat, rat, mouse, dog, cat, rabbit, camel, donkey, deer, mink, chicken, duck, goose, turkey, chicken fight, or human;

preferably, the constant region is derived from a mouse;

preferably, the light chain constant region sequence of the constant region is shown as SEQ ID NO. 9, and the heavy chain constant region sequence of the constant region is shown as SEQ ID NO. 10;

preferably, the functional fragment is selected from any one of VHH, F (ab ') 2, Fab', Fab, Fv and scFv of the antibody.

5. A reagent or a kit for detecting myoglobin, comprising: an antibody or functional fragment thereof according to any one of claims 1 to 4.

6. Use of the antibody or functional fragment thereof according to any one of claims 1 to 4 for the preparation of a reagent or kit for the diagnosis of a disease with abnormal myoglobin levels;

preferably, the disease with abnormal myoglobin level is one selected from acute myocardial infarction and acute coronary syndrome.

7. A method for detecting myoglobin, comprising: mixing the antibody or functional fragment thereof according to any one of claims 1 to 4 with a sample to be tested;

preferably, the method is a method for detecting myoglobin by precipitation reaction or a method for detecting myoglobin by labeling an indicator showing signal intensity;

preferably, the method for detecting myoglobin by precipitation reaction is selected from any one or more of the following methods: a one-way immunodiffusion test, a two-way immunodiffusion test, an immunoturbidimetry, a countercurrent immunoelectrophoresis, an immunoelectrophoresis, and an immunoblotting method;

preferably, the method for detecting myoglobin by marking the indicator showing the signal intensity is selected from any one or more of the following methods: immunofluorescence, radioimmunoassay, enzyme-linked immunoassay, and chemiluminescent immunoassay;

preferably, the indicator is selected from any one of a fluorescent dye, a radioisotope, an enzyme catalyzing color development of a substrate, and a chemiluminescent reagent.

8. A vector comprising a nucleic acid encoding the antibody or functional fragment thereof according to any one of claims 1 to 4.

9. A host cell comprising the vector of claim 8.

10. A method for producing the antibody or functional fragment thereof according to any one of claims 1 to 4, comprising:

culturing the host cell of claim 9, and isolating and purifying the antibody or functional fragment thereof from the culture medium or from the cultured host cell.